Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
Targeted Oncology · 2024
DOI: 10.1007/s11523-024-01047-y ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Targeted Oncology, 2024. Verfasst von Taizo Uchimoto und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, SGH Foundation, Kenzo Suzuki Memorial Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, has been used for patients with metastatic urothelial carcinoma (mUC) after progressing on checkpoint inhibitors (CPIs). Re-challenging chemotherapy with platinum agents and continuing CPIs beyond progressive disease (PD) have often been chosen following PD on CPIs, and several studies indicate favorable treatment effects of re-challenging chemotherapy. There is little evidence for comparing EV and re-challenging chemotherapy in real-world clinical practice. OBJECTIVE: The aim was to reveal the real-world treatment outcomes of EV, re-challenging chemotherapy, and continuing CPIs beyond PD in mUC patients. PATIENTS AND METHODS: A multi-institutional dataset of 350 mUC patients treated with CPIs was utilized. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) were evaluated to compare the treatment arms. RESULTS: One hundred and nine mUC patients were treated with EV with a median follow-up of 6.4 months. The ORR and disease control rate (DCR) were 48% and 70%, respectively. The OS from PD on pembrolizumab exhibited significant differences among the three groups, with a median OS of 8, 14, and 29 months in continuing pembrolizumab beyond PD, re-challenging chemotherapy, and EV, respectively. When comparing the survival outcomes from the initiation of the treatment, there is neither a difference in OS (p = 0.124), PFS (p = 0.936), nor ORR (p = 0.816) between EV and re-challenging chemotherapy. Notably, the DOR in patients who achieved an objective response was significantly longer in the EV group than the re-challenging chemotherapy group (a median of 11 and 5 months, p = 0.049). For OS, the difference was not statistically significant (27 and 11 months in EV and re-challenging chemotherapy, respectively: p = 0.05). CONCLUSIONS: A superior effect of EV on patient survival compared to re-challenging chemotherapy and continuing pembrolizumab beyond PD was observed in our real-world analysis, which is attributed to the durable DOR in EV treatment despite the similar ORR to re-challenging chemotherapy. Enfortumab vedotin (EV) is an antibody–drug conjugate targeting Nectin-4 and is now utilized for patients with metastatic urothelial carcinoma following treatment with checkpoint inhibitors (CPIs). Until recently, repeating chemotherapy using platinum drugs or continuing CPIs were often the treatments used for these patients. In the present study, we reported real-world treatment outcomes, mainly focusing on EV and repeating chemotherapy. Although the objective responses to the treatments were comparable, the duration of response for patients responding to the treatment was significantly longer in patients treated with EV than in those repeating chemotherapy, resulting in extended survival time with EV treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
- Department of Urology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan. kazumasa.komura@ompu.ac.jp.
- Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan.
- Department of Urology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
- Department of Urology, Fujita-Health University School of Medicine, 1-98 Dengakugakubo Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
- Department of Urology, Kindai University Faculty of Medicine, 377-2, Oono-higashi, Osakasayama, Osaka, 589-8511, Japan.
ORCID-Profile: Taizo Uchimoto
Förderung
- Japan Society for the Promotion of Science
- SGH Foundation
- Kenzo Suzuki Memorial Foundation
- Naito Foundation
- Japanese Urological Association
Zitieren
APA
Uchimoto, T., Tsuchida, S., Komura, K., Fukuokaya, W., Adachi, T., Hirasawa, Y., Hashimoto, T., Yoshizawa, A., Saruta, M., Hashimoto, M., Higashio, T., Matsuda, T., Nishimura, K., Tsujino, T., Nakamura, K., Fukushima, T., Nishio, K., Yamamoto, S., Iwatani, K., …, & Azuma, H. (2024). Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors. Targeted Oncology. https://doi.org/10.1007/s11523-024-01047-y
Vancouver
Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, et al. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors. Targeted Oncology. 2024. doi:10.1007/s11523-024-01047-y
BibTeX
@article{Uchimoto2024,
author = {Uchimoto, Taizo and Tsuchida, Shuya and Komura, Kazumasa and Fukuokaya, Wataru and Adachi, Takahiro and Hirasawa, Yosuke and Hashimoto, Takeshi and Yoshizawa, Atsuhiko and Saruta, Masanobu and Hashimoto, Mamoru and Higashio, Takuya and Matsuda, Takuya and Nishimura, Kazuki and Tsujino, Takuya and Nakamura, Ko and Fukushima, Tatsuo and Nishio, Kyosuke and Yamamoto, Shutaro and Iwatani, Kosuke and Urabe, Fumihiko and Mori, Keiichiro and Yanagisawa, Takafumi and Tsuduki, Shunsuke and Takahara, Kiyoshi and Inamoto, Teruo and Miki, Jun and Fujita, Kazutoshi and Kimura, Takahiro and Ohno, Yoshio and Shiroki, Ryoichi and Uemura, Hirotsugu and Azuma, Haruhito},
title = {Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors},
journal = {Targeted Oncology},
year = {2024},
doi = {10.1007/s11523-024-01047-y}
}
EUVIMED